Meta tags:
description=NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.;

Headings (most frequently used words):

in, the, of, and, disease, to, parkinson, on, treatment, care, data, phase, trial, for, md, lrrk2, agitation, clinical, role, patient, generalized, myasthenia, gravis, therapies, early, biomarkers, right, study, news, with, therapeutic, primary, an, expert, into, management, from, identify, 2026, csf, shared, advanced, ms, real, world, pd, highlights, emerging, meets, safety, neurovoices, brain, chat, education, thymidine, kinase, deficiency, tk2d, illustrations, commentaries, visualizing, as, precision, pa, integrating, advances, recognition, paraneoplastic, lems, gmg, how, do, patients, neurologylive, neurology, pathway, activation, sporadic, associated, matching, what, transitions, nipocalimab, improves, stage, agonist, kamalini, galvelis, gba1, risk, variant, agents, watch, cerebral, palsy, gluten, free, diet, linked, quality, life, biomarker, solengepras, endpoint, arise, frontotemporal, dementia, diagnosis, head, impacts, approaches, thrive, eptinezumab, impact, migraine, after, prior, cgrp, failure, action, multiple, sclerosis, gray, areas, mechanism, antipsychotic, therapy, dextromethorphan, bupropion, latest, conference, coverage, shorts, dr, gatson, living, oncology, brainstorm, column, mind, moments, podcast, focus, nerdy, neurologist, videos, podcasts, continuing, medical, increasing, awareness, options, nashville, shining, light, ultra, rare, closer, look, at, dystrophin, dysregulation, target, duchenne, muscular, dystrophy, starnet, show, me, turning, molecular, drivers, cns, tumors, putting, first, acute, pain, guide, incorporating, cutting, edge, science, their, strategies, cells, targets, unlocking, future, glioma, recent, personalize, clue, rapid, coordinated, sclc, collaborating, across, continuum, novel, multidisciplinary, plans, community, collab, evolving, fcrn, inhibitors, suspicion, stabilization, mogad, improving, outcomes, through, identification, all, trending, insights, friday, october, overlap, years, perimenopause, menopause, christen, kutz, phd, reveal, about, new, reveals, plasma, highlight, distinct, biological, responses, lecanemab, alzheimer, metabolic, agent, vutiglabridin, motor, scores, oral, d1, d2, lu, af28996, increases, good, time, 1b, dare2, begins, why, diverse, cohorts, matter, replicating, intronic, forum, shifting, paradigm, nf1, plexiform, neurofibroma, ahead, mds, benjamin, walter, mba, cord, blood, cannabinoids, 12, month, cognitive, improvements, glp, gip, kp405, shows, signal, link, arv, 102, degradation, oculomotor, changes, inhibitor, biib122, fails, slow, fda, update, september, approvals, clearances, priority, review, beyond, mri, serum, cognition, defining, medicine, decision, making, specialty, trajectory, drives, selection, between, two, label, sleep, disorders, actually, drive, neurodegenerative, design, population, zorevunersen, works, validating, african, ancestry, generation, assessing, deterioration, gefurulimab, prevail, james, winkley, long, term, rethinking, model, etiology, over, symptom, understanding, dravet, syndrome, its, burden, moving, needle, stroke, recurrence, limited, access, eva, mistry, azetukalner, nda, submitted, ema, gives, approval, recommendation, ocrelizumab, fusion, end, points, realistic, possibility, reversing, diabetic, neuropathy, dosing, drug, interactions, pivotal, trials, efficacy, closing, gaps, cluster, headache, jennifer, fokas, minali, nigam,

Text of the page (most frequently used words):
and (48), the (48), disease (39), 2026 (36), parkinson (30), more (21), october (20), ago (20), view (19), #treatment (18), days (18), phase (17), news (14), phd (14), trial (13), with (13), mds (13), #neurology (12), care (12), for (12), slide (12), data (11), lrrk2 (11), clinical (10), early (9), therapies (8), marco (8), meglio (8), louie (8), pasculli (8), brain (8), study (8), biomarkers (7), neurologylive (7), advertisement (7), from (7), how (7), 7th (7), video (7), about (6), advanced (6), right (6), patient (6), identify (6), shared (6), associated (6), expert (6), biomarker (6), agonist (6), generalized (6), myasthenia (6), gravis (6), world (6), role (6), next (6), previous (6), september (6), agitation (6), multiple (6), sclerosis (6), all (5), life (5), emerging (5), csf (5), primary (5), stage (5), 6th (5), cognitive (5), patients (5), what (5), real (5), chat (5), now (5), disorders (5), oct (5), contact (4), migraine (4), pathway (4), activation (4), sporadic (4), meets (4), insights (4), results (4), gluten (4), free (4), diet (4), quality (4), motor (4), benjamin (4), walter (4), mba (4), discusses (4), advances (4), are (4), therapy (4), gba1 (4), variant (4), kamalini (4), galvelis (4), mph (4), neurovoices (4), why (4), time (4), christen (4), kutz (4), nipocalimab (4), therapeutic (4), faan (4), management (4), into (4), sleep (4), highlights (3), dementia (3), matching (3), solengepras (3), endpoint (3), arise (3), showed (3), that (3), investigational (3), improvements (3), changes (3), kp405 (3), glp (3), gip (3), shows (3), suggest (3), month (3), linked (3), cerebral (3), palsy (3), ahead (3), medicine (3), recognition (3), risk (3), oral (3), good (3), begins (3), vutiglabridin (3), scores (3), improves (3), alzheimer (3), new (3), landscape (3), transitions (3), mitzi (3), joi (3), williams (3), medical (3), james (3), gmg (3), multimedia (3), future (3), guide (3), precision (3), person (3), virtual (3), event (3), headache (3), podcasts (3), safety (3), podcast (3), design (3), oncology (3), recap (3), shorts (3), fda (3), conference (3), events (3), resources (3), mjh (2), your (2), privacy (2), conditions (2), not (2), board (2), thrive (2), eptinezumab (2), impact (2), after (2), prior (2), cgrp (2), failure (2), frontotemporal (2), diagnosis (2), head (2), impacts (2), approaches (2), biib122 (2), slow (2), compared (2), placebo (2), 5th (2), findings (2), arv (2), 102 (2), function (2), neuroinflammation (2), signal (2), cells (2), cannabinoids (2), show (2), highlighting (2), blood (2), agents (2), watch (2), genetic (2), informing (2), deep (2), stimulation (2), earlier (2), forum (2), jessica (2), discussed (2), options (2), changing (2), paradigm (2), nf1 (2), plexiform (2), african (2), ancestry (2), isabella (2), ciccone (2), diverse (2), cohorts (2), matter (2), replicating (2), intronic (2), dyskinesia (2), af28996 (2), increases (2), dare2 (2), symptom (2), metabolic (2), agent (2), carlos (2), cruchaga (2), based (2), biological (2), responses (2), lecanemab (2), outcomes (2), its (2), reveal (2), between (2), their (2), including (2), decision (2), making (2), overlap (2), years (2), perimenopause (2), menopause (2), evolving (2), selection (2), across (2), improving (2), fasco (2), ruham (2), nasany (2), paraneoplastic (2), lems (2), howard (2), integrating (2), illustrations (2), commentaries (2), visualizing (2), muscular (2), dystrophy (2), light (2), rare (2), thymidine (2), kinase (2), deficiency (2), tk2d (2), education (2), say (2), episode (2), cluster (2), rethinking (2), gaps (2), dextromethorphan (2), bupropion (2), gray (2), areas (2), reversing (2), diabetic (2), neuropathy (2), stroke (2), mechanism (2), antipsychotic (2), videos (2), nerdy (2), neurologist (2), read (2), weekly (2), exclusive (2), experts (2), mind (2), moments (2), column (2), neuro (2), brian (2), callaghan (2), network (2), kuanghua (2), guo (2), neurodegeneration (2), defining (2), action (2), specialty (2), aanem (2), coverage (2), parkinsonism (2), practical (2), live (2), authors (2), demyelinating (2), subscribe (2), publications (2), partners (2), cme (2), conferences (2), media (2), home, rights, reserved, sciences, 259, prospect, plains, bldg, cranbury, 08512, info, choices, terms, sell, information, advertise, editorial, advisory, trending, full, luma, dnl151, did, confirmed, worsening, inhibitor, fails, protac, degrader, was, saccadic, hypometria, markers, endolysosomal, synaptic, integrity, axonal, guidance, participants, link, degradation, oculomotor, exploratory, extracellular, vesicle, suggested, penetrant, engaged, insulin, signaling, pathways, small, late, breaking, may, affect, measures, although, significant, were, observed, seven, baby, tooth, stem, botulinum, toxin, mixed, key, milestones, cord, testing, characterization, alongside, developments, adaptive, efforts, philadelphia, schulte, nyu, grossman, school, systemic, neurofibromas, shifting, neurofibroma, associate, vice, president, research, foundation, large, scale, replication, rs3115534, noncoding, tied, people, dopamine, prodrug, boosts, cuts, off, reduces, levodopa, 800, significantly, improved, director, neurogenomics, informatics, center, washington, university, monitoring, reveals, plasma, highlight, distinct, retrospective, survey, providers, examining, transitioning, joined, jakai, mcewen, charnetta, colton, poole, discuss, challenges, communication, health, teams, navigating, language, promoting, advocating, clear, centered, plenary, speaker, infusion, focused, ultrasound, when, consider, device, aided, can, individualized, hubert, fernandez, cerebrospinal, fluid, potentially, development, targeting, 8th, michael, levy, jeffrey, bennett, eoin, flanagan, bch, mogad, through, identification, charu, aggarwal, erminia, massarelli, suspicion, stabilization, tuan, community, collab, fcrn, inhibitors, abigail, schwaede, alexis, lizarraga, collaborating, continuum, novel, multidisciplinary, plans, millie, das, wade, iams, msci, clue, rapid, coordinated, sclc, vinay, puduvalli, manmeet, ahluwalia, girish, dhall, unlocking, glioma, recent, personalize, katherine, ruzhansky, targets, oswald, jeremy, adler, dmsc, amanda, nasser, putting, first, acute, pain, incorporating, cutting, edge, science, strategies, november, turning, molecular, drivers, cns, tumors, anne, connolly, amy, moore, dystrophin, dysregulation, target, duchenne, starnet, zarazuela, zolkipli, cunningham, mbchb, mrcp, mary, kay, koenig, perry, shieh, fana, shining, ultra, closer, look, nashville, register, increasing, awareness, continuing, better, talk, healthcare, team, 175, advancing, ways, treating, dysfunction, assessment, 176, bbp, 418, lgmd, closing, jennifer, fokas, minali, nigam, pivotal, trials, efficacy, dosing, drug, interactions, realistic, possibility, azetukalner, nda, submitted, ema, gives, approval, recommendation, ocrelizumab, fusion, end, points, moving, needle, recurrence, limited, access, eva, mistry, understanding, dravet, syndrome, burden, model, etiology, over, long, term, learn, check, out, hosted, specialist, every, ongoing, featured, focus, series, depth, conversations, variety, listen, biweekly, brings, you, interviews, this, translates, complex, topics, accessible, evidence, gatson, living, brainstorm, year, outlook, peripheral, other, nerve, teaching, dpn, 26th, car, cell, cidp, 3rd, symptoms, could, help, before, starts, robert, bermel, true, day, compounding, effect, apnea, marisa, mcginley, hours, single, neurofilament, result, falls, short, assessing, deterioration, gefurulimab, prevail, winkley, validating, generation, zorevunersen, works, population, actually, drive, neurodegenerative, drives, two, label, trajectory, cognition, beyond, mri, serum, update, approvals, clearances, priority, review, friday, latest, upcoming, spotlight, choose, insomnia, excessive, daytime, sleepiness, narcolepsy, diseases, ataxia, chronic, inflammatory, polyneuropathy, neuromuscular, huntington, movement, nmosd, epilepsy, account, sponsored, job, interactive, tools, giants, leaders, features, international, journal, bridging, listing, roundtable, discussions, peers, perspectives, medcast, peer, exchange, special, report, cure, connections,

Text of the page (random words):
rology expert insights news media all videos medical world news podcasts weekly recap cure connections insights special report neurologylive peer exchange medcast peers perspectives roundtable discussions shorts shows podcasts conferences conference coverage conference listing cme ce more partners publications neurologylive bridging the gaps international journal of ms care resources expert authors fda news features future leaders in neurology giants of multiple sclerosis interactive tools job board live events neurology resources parkinsonism practical guide sponsored the g l o b virtual events subscribe my account news media conferences cme ce partners publications resources subscribe dementia and alzheimer disease epilepsy genetic disorders headache and migraine migraine ms and demyelinating disorders nmosd multiple sclerosis movement disorders parkinson disease dyskinesia huntington disease neuro oncology neuromuscular chronic inflammatory demyelinating polyneuropathy muscular dystrophy ataxia rare diseases sleep disorders narcolepsy excessive daytime sleepiness insomnia stroke choose specialty spotlight expert authors fda news upcoming live events aanem 2026 parkinsonism practical guide advertisement conference coverage previous slide next slide view more 3 days ago mds solengepras meets primary endpoint in phase 3 arise trial of parkinson disease 3 days ago mds csf biomarkers identify shared lrrk2 pathway activation in sporadic and lrrk2 associated parkinson disease 3 days ago mds advanced therapies in parkinson disease matching the right treatment to the right patient 4 days ago aanem christen kutz phd pa c on what real world data reveal about treatment transitions to nipocalimab in generalized myasthenia gravis 4 days ago mds metabolic agent vutiglabridin improves motor scores in early stage study of parkinson disease 4 days ago mds oral d1 d2 agonist lu af28996 increases good on time in phase 1b advanced pd study phase 2 dare2 trial begins 4 days ago mds neurovoices kamalini galvelis ms on why diverse cohorts matter in replicating a gba1 intronic risk variant 4 days ago mds emerging advances in parkinson disease ahead of mds 2026 benjamin walter md mba 5 days ago mds 12 month gluten free diet linked to cognitive quality of life improvements in parkinson disease 5 days ago mds glp 1 gip agonist kp405 shows biomarker signal in parkinson disease latest news view more oct 09 2026 news neurologylive friday 5 october 9 2026 frontotemporal dementia diagnosis head impacts and emerging treatment approaches oct 08 2026 fda action update september 2026 approvals clearances and priority review oct 08 2026 phase 4 thrive data highlights eptinezumab s impact on migraine after prior cgrp failure oct 08 2026 solengepras meets primary endpoint in phase 3 arise trial of parkinson disease oct 08 2026 previous slide next slide beyond mri the role of serum biomarkers in multiple sclerosis 7 cerebral palsy agents to watch gluten free diet improves cognition and quality of life in pd real world data on treatment transitions to nipocalimab in gmg defining precision medicine in multiple sclerosis shared decision making for agitation in specialty care and disease trajectory what drives treatment selection between the two on label agitation therapies gray areas do sleep disorders actually drive neurodegenerative disease the study design and patient population how zorevunersen works the mechanism of action validating an african ancestry linked gba1 risk variant in pd generation kamalini galvelis ms assessing clinical deterioration with gefurulimab in the prevail trial james winkley md advertisement shorts view all shorts 0 42 why a single neurofilament light result falls short in ms 13 hours ago by marisa mcginley do 1 22 the compounding effect of sleep apnea on neurodegeneration a day ago by kuanghua guo md phd 0 42 defining true precision medicine in multiple sclerosis 2 days ago by robert bermel md 1 17 how sleep symptoms could help identify neurodegeneration before it starts 2 days ago by kuanghua guo md phd 1 01 recap neurology news network october 3rd 7 days ago by louie pasculli 0 46 improving future cidp trial design 9 days ago by marco meglio 1 more 1 16 primary phase 2 results for car t cell therapy in gmg 10 days ago by marco meglio 1 more 1 17 recap neurology news network september 26th 14 days ago by louie pasculli 0 57 what other nerve conditions are teaching us about reversing dpn 15 days ago by brian callaghan md ms 0 57 the 5 to 10 year outlook for diabetic peripheral neuropathy 16 days ago by brian callaghan md ms previous slide next slide the g l o b dr gatson s living oncology brainstorm column this new column translates complex neuro oncology topics into accessible evidence based insights view now mind moments podcast mind moments is a biweekly podcast from neurologylive that brings you exclusive interviews with neurology experts listen now neurovoices neurovoices is weekly series of in depth exclusive q a conversations with a variety of experts in neurology read now clinical trial in focus every month an ongoing clinical trial in the landscape of neurology is featured highlighting the design of the study read now brain chat with the nerdy neurologist check out the brain chat with the nerdy neurologist podcast hosted by multiple sclerosis specialist mitzi joi williams md learn more videos view more previous slide next slide long term and real world safety data on antipsychotic agitation therapy mechanism and trial data for an antipsychotic agitation therapy rethinking the disease model etiology over symptom understanding dravet syndrome the disease and its burden moving the needle on stroke recurrence in patients with limited access to care eva mistry md azetukalner nda submitted ema gives approval recommendation to ocrelizumab phase 3 fusion trial meets end points gray areas realistic possibility of reversing diabetic neuropathy safety dosing and drug interactions for dextromethorphan bupropion in agitation pivotal trials efficacy and safety of dextromethorphan bupropion in agitation closing the gaps in cluster headache care jennifer fokas md minali nigam md podcasts october 7 2026 brain chat the overlap years perimenopause menopause and ms september 30 2026 episode 176 bbp 418 and the changing treatment landscape of lgmd september 25 2026 cognitive dysfunction in ms rethinking assessment and management september 18 2026 episode 175 advancing the ways of treating cluster headache september 11 2026 brain chat say it more say it better how to talk with your healthcare team previous slide next slide continuing medical education view more in person event increasing awareness of therapeutic options for thymidine kinase 2 deficiency tk2d october 16 2026 register now in person virtual event primary care education in nashville october 20 21 2026 view more multimedia shining a light on an ultra rare disease a closer look at thymidine kinase 2 deficiency tk2d zarazuela zolkipli cunningham mbchb mrcp mary kay koenig md perry shieh md phd faan fana view more video expert illustrations commentaries visualizing the role of dystrophin dysregulation as a therapeutic target in duchenne muscular dystrophy and md starnet anne m connolly md faan amy moore phd view more in person virtual event show me the data turning molecular drivers into precision care for cns tumors november 12 2026 view more video putting the patient first in acute pain management the pa s guide to incorporating cutting edge science into their treatment strategies jessica oswald md mph jeremy a adler dmsc pa c amanda nasser ms np view more video expert illustrations commentaries visualizing the role of b cells as therapeutic targets for generalized myasthenia gravis james f howard jr md faan katherine ruzhansky md ms view more multimedia unlocking the future of glioma care integrating recent advances to personalize treatment vinay k puduvalli md manmeet ahluwalia md mba fasco girish dhall md view more video from clue to care rapid recognition and coordinated management of paraneoplastic lems in sclc millie das md wade iams md msci ruham nasany md view more video collaborating across the continuum integrating novel therapies into multidisciplinary treatment plans for generalized myasthenia gravis abigail schwaede md alexis lizarraga md ms view more multimedia community collab the evolving role of fcrn inhibitors in the management of generalized myasthenia gravis gmg james f howard jr md faan tuan vu md view more video from suspicion to stabilization early recognition and treatment of paraneoplastic lems charu aggarwal md mph fasco erminia massarelli md phd ms ruham nasany md view more video how do i identify mogad improving outcomes through early identification of patients michael levy md phd jeffrey l bennett md phd eoin p flanagan mb bch view more previous slide next slide advertisement all news advertisement csf biomarkers identify shared lrrk2 pathway activation in sporadic and lrrk2 associated parkinson disease by louie pasculli october 8th 2026 new cerebrospinal fluid biomarker data suggest shared lrrk2 pathway activation across sporadic and lrrk2 associated parkinson disease potentially informing biomarker development and therapeutic targeting advanced therapies in parkinson disease matching the right treatment to the right patient by hubert fernandez md louie pasculli october 7th 2026 an mds 2026 plenary speaker discusses the evolving role of infusion therapies deep brain stimulation and focused ultrasound in parkinson disease including when to consider device aided therapies and how treatment selection can be individualized brain chat the overlap years perimenopause menopause and ms by mitzi joi williams md october 7th 2026 mitzi joi williams md is joined by jakai mcewen do and charnetta colton poole md to discuss the challenges of communication between patients and their health care teams including navigating medical language promoting shared decision making and advocating for clear patient centered care christen kutz phd pa c on what real world data reveal about treatment transitions to nipocalimab in generalized myasthenia gravis by marco meglio christen kutz phd pa c october 7th 2026 christen kutz phd pa c discusses a retrospective survey of neurology providers examining why patients with generalized myasthenia gravis are transitioning to nipocalimab and what real world outcomes data suggest about its role in the treatment landscape new study reveals plasma biomarkers highlight distinct biological responses to lecanemab in alzheimer disease by louie pasculli carlos cruchaga phd october 7th 2026 carlos cruchaga phd director of the neurogenomics and informatics center at washington university discusses emerging blood based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in alzheimer disease metabolic agent vutiglabridin improves motor scores in early stage study of parkinson disease by marco meglio october 7th 2026 phase 2a trial results showed 800 mg vutiglabridin significantly improved motor symptom scores compared with placebo in early stage parkinson s disease oral d1 d2 agonist lu af28996 increases good on time in phase 1b advanced pd study phase 2 dare2 trial begins by isabella ciccone mph october 7th 2026 investigational oral dopamine agonist prodrug boosts good on time cuts off time and dyskinesia and reduces levodopa in advanced parkinson disease as phase 2 begins neurovoices kamalini galvelis ms on why diverse cohorts matter in replicating a gba1 intronic risk variant by isabella ciccone mph kamalini galvelis ms october 7th 2026 the associate vice president of clinical research at the parkinson s foundation discussed a large scale replication of rs3115534 g a noncoding gba1 variant tied to parkinson disease in people of african ancestry clinical forum highlights shifting paradigm in nf1 plexiform neurofibroma care by marco meglio october 6th 2026 at a neurologylive clinical forum in philadelphia jessica d schulte md phd of nyu grossman school of medicine discussed how earlier recognition and systemic therapy options are changing the treatment paradigm for patients with nf1 associated plexiform neurofibromas emerging advances in parkinson disease ahead of mds 2026 benjamin walter md mba by benjamin l walter md louie pasculli october 6th 2026 benjamin walter md mba discusses how advances in biomarker testing and genetic characterization are informing parkinson disease care alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier advertisement from cord blood to cannabinoids 7 agents to watch in cerebral palsy by marco meglio october 6th 2026 seven investigational cerebral palsy therapies from baby tooth stem cells to cannabinoids and botulinum toxin show mixed early results highlighting key clinical trial milestones ahead 12 month gluten free diet linked to cognitive quality of life improvements in parkinson disease by louie pasculli october 6th 2026 late breaking findings from mds 2026 suggest a gluten free diet may affect cognitive and quality of life measures in parkinson disease although no significant changes in motor function were observed glp 1 gip agonist kp405 shows biomarker signal in parkinson disease by marco meglio october 6th 2026 exploratory extracellular vesicle biomarkers suggested kp405 a brain penetrant glp 1 gip agonist engaged insulin signaling and neuroinflammation pathways in a small phase 1 study phase 1 data link arv 102 lrrk2 degradation to oculomotor and csf biomarker changes in parkinson disease by louie pasculli october 5th 2026 early phase 1 findings showed that the protac lrrk2 degrader arv 102 was associated with improvements in saccadic hypometria and changes in csf markers of endolysosomal function neuroinflammation synaptic integrity and axonal guidance in participants with parkinson disease lrrk2 inhibitor biib122 fails to slow early stage parkinson disease by marco meglio october 5th 2026 full results from the phase 2b luma showed that investigational biib122 dnl151 did not slow confirmed clinical worsening in early stage parkinson s disease compared with placebo view all news advertisement advertisement trending on neurologylive clinical neurology news and neurology expert insights 1 solengepras meets primary endpoint in phase 3 arise trial of parkinson disease 2 csf biomarkers identify shared lrrk2 pathway activation in sporadic and lrrk2 associated parkinson disease 3 advanced therapies in parkinson disease matching the right treatment to the right patient 4 frontotemporal dementia diagnosis head impacts and emerging treatment approaches 5 phase 4 thrive data highlights eptinezumab s impact on migraine after prior cgrp failure about us advisory board editorial contact us advertise contact mjh ls do not sell my information terms and conditions privacy your privacy choices contact info 259 prospect plains rd bldg h cranbury nj...